Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization by Simoons, Maarten L & Windecker, Stephan
REVIEW
Controversies in Cardiovascular Medicine
Chronic stable coronary artery disease: drugs
vs. revascularization
Maarten L. Simoons1 and Stephan Windecker2*
1Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands; and 2Department of Cardiology, Bern University Hospital, CH-3010
Bern, Switzerland
Received 10 September 2009; revised 22 November 2009; accepted 11 December 2009; online publish-ahead-of-print 26 January 2010
Coronary artery disease remains the leading cause of mortality in most industrialized countries, although age-standardized mortality related to
coronary artery disease (CAD) has decreased bymore than 40% during the last two decades. Coronary atherosclerosismay cause angina pectoris,
myocardial infarction, heart failure, arrhythmia, and sudden death. Medical management of atherosclerosis and its manifestation aims at retardation
of progression of plaque formation, prevention of plaque rupture, and subsequent events and treatment of symptoms, when these occur as well as
treatment of the sequelae of the disease. Revascularization by either percutaneous coronary intervention (PCI) or coronary artery bypass surgery
(CABG) is performed as treatment of flow-limiting coronary stenosis to reduce myocardial ischaemia. In high-risk patients with acute coronary
syndromes (ACS), a routine invasive strategy with revascularization in most patients provides the best outcome with a significant reduction in
death and myocardial infarction compared with an initial conservative strategy. Conversely, the benefit of revascularization among patients
with chronic stable CAD has been called into question. This review will provide information that revascularization exerts favourable effects on
symptoms, quality of life, exercise capacity, and survival, particularly in those with extensive CAD and documented moderate-to-severe ischaemia.
Accordingly, CABG and PCI should be considered a valuable adjunct rather than an alternative to medical therapy.
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Introduction
Coronary artery disease (CAD) remains the leading cause of mor-
tality in most industrialized countries, although age-standardized
mortality related to CAD has decreased by more than 40% during
the last two decades.1,2 Half of this decline resulted from prevention
and reduction in major risk factors, whereas the other half has been
attributed to medical treatment and revascularization.3 Coronary
artery disease is the result of atherosclerosis, a progressive disorder
of the vessel walls, with formation of plaques throughout the arterial
system.4 Vascular inflammation may lead to disruption of the endo-
thelium overlying a plaque and cause subsequent intravascular
thrombosis.5,6 Symptoms related to atherosclerosis vary depending
on the location and degree of stenosis of the vessels and the occur-
rence, site, and severity of plaque disruption. Coronary athero-
sclerosis may thus be asymptomatic or cause angina pectoris,
myocardial infarction (MI), heart failure, arrhythmias, and sudden
death.4 Medical management of atherosclerosis and its manifestation
aims at retardation of progression of plaque formation, prevention
of plaque rupture, and subsequent events and treatment of symp-
toms, when these occur as well as treatment of the sequelae of
the disease. Revascularization by either percutaneous coronary inter-
vention (PCI) or coronary artery bypass surgery (CABG) is per-
formed as treatment of flow-limiting coronary stenosis to reduce
myocardial ischaemia and its manifestations.
In high-risk patients with acute coronary syndromes (ACS, with or
without ST-segment elevation) a routine invasive strategy with revas-
cularization in most patients provides the best outcomewith a signifi-
cant reduction in death and MI compared with an initial conservative
strategy.7–10 Conversely, the benefit of revascularization among
patients with chronic stable CAD has been called into question
(Table 1).11–13 In particular, the appropriateness of PCI has been chal-
lenged because many patients undergoing PCI lack documentation
of ischaemia by non-invasive testing prior to the procedure,14
the incremental cost,15 and an alleged lack of survival benefit.12,16,17
Therefore, in this review we discuss the indications for
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revascularization in patients with ‘stable’ CAD, in the context of the
incidence of angina pectoris and its prognosis, as well as established
and new anti-angina drugs. Preventive medical therapy is well
described in current guidelines and outside the scope of this review.18
Prevalence, incidence, and
prognosis of angina pectoris
The prevalence of CAD varies widely across Europe, with high rates
in the northern and eastern countries and lower rates in the south
and west.19 Overall the prevalence of angina is estimated at 20–40
per 1000 inhabitants. It is higher in men than in women at a similar
age, and varies 10-fold between the ages of 50 and 70 years.20 A
recent study from Finland describes the incidence of angina as a
first manifestation of CAD.21 The incidence calculated from new pre-
scriptions of nitrates was remarkably similar among men and women.
In contrast, the incidence of new angina defined by an abnormal stress
test was almost twice as high in men, as in women. This confirms
earlier reports of underuse of diagnostic tests in women.20 Overall
the incidence of angina by either definition varied from 4–7 at age
45–54 to 42–45 at age 85–89. The age of new angina was lower
in men (68+11 years) than in women (72+10 years). However,
the prognostic implications were similar in both sexes.21 Patients
with angina had a substantially higher mortality risk than the
average population, with standard mortality rates around 2–5 at
age 45–65, and around 1–2 at age 75–89.
While mortality rates for acute manifestations of CAD have
declined in recent years, mortality from stable CAD has not
changed significantly over the last decades.22 Furthermore it
should be noted that in the Finnish study, the rate of fatal and non-
fatal MI was higher than the rates reported in recent clinical trials
of patients with angina or stable CAD.21,23–25 This underscores
the fact that trials include selected groups of patients, often at
lower risk than those in actual clinical practice.
Pathophysiology of stable
coronary artery disease
Assessment of the severity of coronary
artery disease
Advanced age, left-ventricular function (ejection fraction), and
the extent and severity of coronary stenosis as assessed at the
time of diagnostic coronary angiography and the presence or
absence of more extensive atherosclerosis in other vascular beds
are the most important prognostic factors in patients with
established CAD.
Several risk-scores, based on clinical factors have been proposed
to predict the risk for MI or death in patients with stable CAD.26
Also a simple classification into single-, double-, triple-, and left
main CAD is clinically useful and is a major prognostic indicator
during long-term follow-up of angiography studies.27,28 Additional
prognostic information is provided by the severity of coronary
artery obstruction and its location, which are combined in the
CAD jeopardy score, the Duke prognostic CAD index, and
more recently the SYNTAX score.29–32 Taken together these
data provide a gradient of risk with more extensive and severe
CAD portending worse prognosis.
Assessment of lesion severity is mostly based on coronary
angiography, while the structure of the vessel wall and plaque
morphology may be studied with intravascular ultrasound or
optical coherence tomography.33,34 Obstructive coronary artery
lesions progressively restrict the ability to increase blood flow in
response to changing metabolic demands and lead to myocardial
ischaemia at rest or during exercise.35 Generally, compensatory
vasodilatory mechanisms are exhausted with lesions exceeding
80% of lumen diameter,36 while dysfunction of the endothelium
or spasm may aggravate a stenosis caused by a coronary plaque
(Figure 1).37,38
The advent of sensor-tipped guidewires allows for physiological
determination of lesion significance by measuring fractional
flow reserve (FFR) during pharmacologically induced maximal
hyperaemia.39 A threshold of FFR ,80% has been correlated
with ischaemia as detected by nuclear imaging procedures or
stress echocardiography and constitutes a criterion for
revascularization.40
Manifestations of chronic myocardial
ischaemia
Myocardial ischaemia typically elicits a cascade of events character-
ized by diastolic and systolic ventricular dysfunction with regional
wall motion abnormalities, ST-segment changes, and the develop-
ment of ischaemic pain (angina pectoris). Prolonged myocardial
ischaemia causes myocardial cell death.41
Chronic CAD is by far the commonest cause of heart failure.42
Even in patients with a diagnosis of idiopathic dilated
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Table 1 Clinical presentation and indication for percutaneous coronary interventions in recent all-comer trials and
registries in Europe
EuroHeart Survey120 SIRTAX121 BASKET122 LEADERS123
Chronic stable CAD, % 53 49 42 45
Unstable angina/non-ST elevation MI, % 30 29 36 39
ST-elevation MI, % 16 22 21 16
Approximately half of procedures are performed in patients with acute coronary syndromes, whereas the other half of interventions are in the setting of chronic stable coronary
artery disease.
CAD, coronary artery disease; MI, myocardial infarction.
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cardiomyopathy CAD is frequently found at autopsy.43 Chronic or
repetitive reduction of myocardial perfusion owing to severely
obstructed coronary arteries or collateralized total occlusions
may result in non-contractile but viable myocardium, which
recovers after coronary revascularization, a process referred to
as ‘hibernation’.44,45 In two-thirds of patients with stable CAD
and left-ventricular dysfunction a decline in left-ventricular ejection
fraction was observed during the waiting period prior to CABG,
which resolved at least in part following revascularization.46
Plaque rupture and erosion with thrombotic complications are a
frequent cause of MI and sudden death.6,47 However, ruptured
plaques may go clinically undetected and heal (Figure 2).48
This was confirmed in recent clinical studies using in vivo imaging
which identified superimposed layers of necrotic areas covered by
fibrosis.49 Post-mortem examination of patients who died of acute
MI showed severe underlying coronary artery narrowing with a
mean diameter stenosis of 91% (range 67–99%) at sites of plaque
rupture.50 In contrast, MI in patients most often occurs by
plaque rupture and thrombosis at a ‘non significant’ lesion, i.e. a
plaque with ,50% coronary stenosis at angiography.5,6,47 While
non-obstructive atherosclerotic lesions are by far more prevalent
in the general population than severe lesions and therefore fre-
quently encountered in ACS patients, high-grade coronary artery
stenoses are hazardous and play an ominous role in sudden death
and fatal MI.48,51 These observations support the concept of revas-
cularization by PCI or CABG of coronary lesions causing myocardial
ischaemia whether or not angina is present, provided that such
ischaemia is documented in that patient.
Medical treatment of coronary
artery disease and angina pectoris
In addition to a healthy lifestyle, drug therapy aims at retardation of
progression of atherosclerosis, or perhaps even its regression, and
at prevention of cardiovascular events such as death, MI, or
stroke.18,52 Preventive treatment includes aspirin, statins,
ACE-inhibitors, angiotensin receptor blockers, and b blockers in
patients after MI53 and patients with heart failure. In addition, clo-
pidogrel, prasugrel, and ticagrelor reduce recurrent events in the
first year after an ACS.54–56 It should be appreciated that these
drugs, apart from b blockers, do not reduce angina pectoris or
ischaemia when present.
The numbers needed to treat with these drugs depend on the
risk for future events of a specific patient group. Patients with
stable CAD included in the recent ACTION or EUROPA trials,
who already received different preventive drugs, had an annual
risk of cardiovascular death or MI of about 2.5%.24–26 To avoid
one such event, about 175 patients should be treated during
1 year with aspirin (relative risk reduction 23%), about 120 patients
with a ‘standard dose’ statin (RRR 30%), 200 with an ACE inhibitor
Figure 2 Relationship of stenosis severity and number of preceding plaque ruptures. Data derived from an autopsy study of patients dying
from sudden cardiac death. (Burke et al.48) Stenosis severity positively correlates with the number of previous plaque ruptures for both stable
plaques and those with acute plaque rupture.
Figure 1 Endothelial dysfunction in vessels with atherosclero-
tic coronary artery disease. Intracoronary infusion of acetyl-
choline elicits vasodilatation in normal coronary arteries, but
paradoxical vasoconstriction in vessels with coronary athero-
sclerosis due to insufficient nitric-oxide supply. Obtained with
permission from Ludmer et al.38
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or AT2 receptor blocker (RRR 20%), 200 patients with clopidogrel
in the first year after ACS (RRR 20%), and 240 with high dose statin
(RRR 15% when compared with lower statin dose). In patients at
higher risk, the numbers needed to treat are obviously lower,
and treatment is more cost-effective.
Immediate relief of angina can be provided by nitroglycerine, iso-
sorbide mononitrate, or chewing a nifedipine capsule. Patients may
also be instructed to use these short acting drugs prior to exercise,
in order to reduce the likelihood of subsequent angina. In sympto-
matic patients the frequency of episodes of angina and nitroglycer-
ine consumption can be reduced by long acting nitrates, b
blockers, and calcium antagonists.52 These well-established
agents improve exercise tolerance during a stress test, and
reduce the need for revascularization by PCI or CABG.23
Recently two new classes of drugs have been introduced which
have similar effects as the established agents, albeit through com-
pletely different modes of action.
These drugs have not yet been evaluated by the ESC guideline
committee. Ivabradine reduces heart rate (sinus rhythm) at rest as
well as during exercise by inhibition of the If current in the sino-atrial
node, without any effect on blood pressure, intracardiac conduction,
QT interval, or myocardial contractility. In a series of clinical trials
ivabradine reduced nitroglycerine consumption and improved exer-
cise tolerance during a stress test when compared with placebo in
patients with different background therapies.57–59 In comparative
studies ivabradine was equally effective as atenolol or amlodipine
mono-therapy.58 In a large clinical trial in patients with left-
ventricular dysfunction, ivabradine was safe, even when given in
combination with b blockers and reduced the number of
revascularization procedures during follow-up, in particular in
patients with a resting heart rate above 70 b.p.m., but it did not
reduce the rates of cardiovascular death of MI.60 Up to 25% of
patients receiving ivabradine experience flashes in the eye
or other mild visual symptoms which disappear at continuation of
therapy and rarely are a reason to discontinue the drug.60
Ranolazine selectively inhibits the late sodium influx in the myo-
cardium, which is increased during myocardial ischaemia.61 Thus
ranolazine attenuates the ischaemic abnormalities of ventricular
repolarization and the resulting reduced contractility. In clinical
trials ranolazine improves exercise tolerance and reduces the fre-
quency of angina episodes compared with placebo in patients with
angina pectoris.61 Side effects include nausea, dizziness, and asthe-
nia. Ranolazine causes some prolongation of the QT interval;
however, no significant arrhythmias have been reported. In a
large clinical trial in patients after an ACS no significant reduction
in subsequent death or MI was observed.62
Revascularization in stable
coronary artery disease
Revascularization, relief of ischaemia,
and prognosis
The principal goal of revascularization is the relief of ischaemia to
improve quality of life and exercise capacity, to reduce the amount
of anti-angina drugs, and ultimately improve prognosis on top of
the beneficial effects of medical treatment. Symptomatic and
asymptomatic ischaemia are of prognostic importance in patients
with CAD particularly when occurring at low workload.63,64
Revascularization, by eliminating the target lesion (PCI) or bypass-
ing the narrowed epicardial vessel (CABG), more effectively
relieves myocardial ischaemia than medical treatment alone
(Table 2). For example, in the randomized Asymptomatic Cardiac
Ischemia Pilot (ACIP) study, 57% of patients treated with revascu-
larization were free of ischaemia at 1 year compared with 31 and
36% in the ischaemia-guided and angina-guided strategies, respect-
ively (P, 0.0001). Furthermore, at 2 years follow-up, the risk of
death and MI was significantly lower among patients undergoing
revascularization (4.7%) compared with those receiving ischae-
mia-guided (8.8%) or angina-guided medical treatment (12.1%,
P, 0.04).65 Similarly, patients with silent ischaemia after recent
MI enrolled into the randomized SWISSI II trial showed lower
rates of ischaemia when allocated to PCI (12%) than medical treat-
ment (29%, P ¼ 0.03), a beneficial effect accompanied by improved
left-ventricular ejection fraction (57 vs. 49%, P, 0.001) and an
absolute reduction in clinical events (cardiac death, MI, and revas-
cularization) of 6.3% per year in favour of PCI.66 Along the same
line, patients with angina or exercise-induced ischaemia early
after MI had a better prognosis after revascularization than with
medical therapy alone in the DANAMI study.67 In the myocardial
perfusion substudy of COURAGE, PCI compared with medical
treatment showed a greater absolute reduction in myocardial
ischaemia (22.7 vs. 20.5%, P, 0.0001), and more patients exhib-
ited a relevant reduction in ischaemia (33 vs. 19%, P ¼ 0.0004),
particularly among those with moderate to severe ischaemia
(78 vs. 52%, P ¼ 0.007).68 Again, there was a graded relationship
between reduction of ischaemia and subsequent risk of death or
MI with improved event-free survival in patients with significant
reduction of ischaemia.68
Various observational studies have addressed the impact of
revascularization on prognosis. A myocardial perfusion study of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Relief of ischaemia in trials comparing a
routine invasive with an initial non-invasive strategy in
patients with stable coronary artery disease
Study Routine
revascularization, %
Initial
medical
treatment, %
Kloster et al.74 ETT 56 58
Dakik et al.88 SPECT perfusion defect 212 212
MASS I (CABG)91 ETT 28 54
MASS I (PCI)91 ETT 34 54
MASS II (CABG)96,97 ETT 26 51.1
MASS II (PCI)96,97 ETT 36 51
Hambrecht et al.98 Myocardial perfusion
65 to 78
68 to 77
DECOPI99 ETT 22 22
INSPIRE101 SPECT perfusion deficit 216 215
COURAGE102 SPECT perfusion deficit 22.7 20.5
SWISSI II66 ETT 12 29
Stable CAD: drugs vs. revascularization 533
10 627 patients without prior CAD showed an increasing survival
benefit of revascularization over medical treatment in patients with
moderate to severe ischaemia, whereas no such benefit was appar-
ent in patients with only mild or absence of ischaemia (Figure 3).69
The effect of revascularization on prognosis has also been investi-
gated in a meta-analysis of 24 studies encompassing 3088 patients
with left-ventricular dysfunction (mean LVEF ¼ 32+8%) who
underwent assessment of viability by means of thallium perfusion
imaging, F-18 fluorodeoxy glucose metabolic imaging, or Dobuta-
mine stress echocardiography and were followed for a mean of
25 months.70 In patients with viability, revascularization was associ-
ated with an 80% reduction of risk-adjusted mortality compared
with medical treatment (16%/year vs. 3%/year). This benefit was
most apparent in patients with impaired left-ventricular function.
No benefit was observed in patients without viability at any level
of left-ventricular function.
The Alberta Provincial Project for Outcome Assessment in
CAD (APPROACH) assessed survival according to treatment allo-
cation in 11 661 patients with multivessel CAD undergoing coron-
ary angiography.71 Risk-adjusted mortality was significantly lower
with both CABG (HR ¼ 0.53, CI 0.46–0.61, P, 0.001) and PCI
(HR ¼ 0.65, 95% CI 0.56–0.74, P, 0.001) compared with
medical treatment in the overall cohort as well as patients with
three-vessel CAD, whereas CABG was superior to both PCI and
medical treatment in the subset of patients with left main CAD.
At Duke University Medical Center, 18 481 patients undergoing
coronary angiography between 1986 and 2000 underwent pro-
spective evaluation of risk-adjusted mortality according to treat-
ment assignment.72 During long-term follow-up revascularization
(CABG or PCI) provided a significant survival advantage over
medical treatment in patients with low-, intermediate-, and high-
severity CAD. The absolute survival advantage amounted to 8,
11, and 24 months of life during 15 years of follow-up comparing
CABG with medical treatment. The treatment effect was similar
for CABG and PCI in low- and intermediate severity CAD, but
CABG prevailed over PCI in high-severity CAD. In the EUROPA
study of over 12 000 patients with stable CAD, a risk model was
developed. Risk factors for mortality during 4.2 years follow-up
included elderly age, a history of MI, stroke or peripheral vascular
disease, male gender and diabetes, while previous PCI or CABG
was associated with a reduced risk.26
In summary, revascularization is associated with improved clini-
cal outcome in patients with documented moderate-to-severe
myocardial ischaemia or viable myocardium, in particular when
associated with left-ventricular dysfunction and multivessel CAD.
Randomized trials comparing
revascularization with medical treatment
To date 30 randomized trials have compared medical treatment
with revascularization by means of PCI or CABG in patients with
chronic stable CAD (Table 3).66,67,73–104 The number of patients
included into these trials ranged from 4488 to 2368.104 Coronary
artery bypass surgery was applied as revascularization therapy in
13 trials, of which 6 were performed more than 2 decades ago
using predominantly saphenous vein grafts. Balloon angioplasty
alone was used in eight studies, whereas subsequent trials reported
the use of stents in 9–100% of procedures. Drug-eluting stent
implantation was negligible except for BARI-2D (35% of patients).
Several trials failed to specify the implemented medical treatment.
The majority of studies included predominantly male patients who
were relatively young (with the exception of TIME), had preserved
left-ventricular function and had not undergone previous revascu-
larization by CABG or PCI. One study enrolled exclusively diabetic
patients (BARI-2D).104 Patients were highly selected as randomiz-
ation was performed following delineation of coronary anatomy by
angiography in the vast majority of studies. By design all trials com-
pared treatment strategies (intention-to-treat, routine revasculari-
zation vs. initial medical treatment) allowing subsequent
revascularization when patients deteriorated on medical therapy.
Such ‘cross-over’ from medical treatment to revascularization
was observed in up to half of patients during follow-up. Accord-
ingly the proportion of patients without revascularization progress-
ively diminished during follow-up, potentially blunting differences
between the two strategies.
The largest study comparing PCI with current medical treatment
(COURAGE) enrolled 2287 (6.4%) of 35 539 patients undergoing
eligibility assessment during a 5 year period.102 Half of patients had
minimal or no symptoms of angina and the extent of ischaemia as
assessed by nuclear imaging prior to treatment in a subset of
patients was not severe. The rate of death was similar in the PCI
(7.6%) and medical therapy group (8.3%, HR ¼ 0.87, 95% CI
0.65–1.16, P ¼ 0.38). Non-protocol revascularization procedures
were less frequent among PCI patients (21 vs. 33%, HR ¼ 0.60,
95% CI 0.51–0.71) during follow-up.
The recently reported BARI-2D trial randomly assigned 2368
diabetic patients to medical treatment or revascularization, strati-
fied according to choice of PCI (34%) or CABG (16%). Coronary
revascularization was performed in 97% of patients in the revascu-
larization and 42% of patients in the medical therapy group during
follow-up (Figure 4). The use of drug-eluting stents (35%) was low
as was the prescription of thienopyridines (21%). At 5 years, mor-
tality did not differ between the medical therapy (13.5%) and the
revascularization group (13.2%) in either the CABG or PCI
stratum. Major adverse cardiac events (death, MI, or stroke)
were fewer among patients allocated to revascularization by
Figure 3 Benefit of revascularization in terms of survival is
proportional to the amount of ischaemia as assessed by single
photon emission computed tomography imaging prior to
revascularization. Obtained with permission from Hachomovits
et al.69
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Table 3 Overview of published trials comparing a routine invasive with an initial non-invasive strategy among patients with stable coronary artery disease
Year Inclusion
criteria
Exclusion criteria Number of
patients:
Revasc/OMT
Revasc (PCI,
CABG)
PCI Method
(PTCA, BMS,
DES)
Protocol
Revasc. in
Revasc.Group
Non-protocol
revasc.
in Medical
Group
CAD severity Age
(years)
Female
gender (%)
Diabetes
(%)
Mathur and Guinn73 1977 Chronic stable
CAD
LM-CAD, EF, 15% 56/60 CABG na 98% 7% 1-vs. CAD 16%;
2-vs. CAD 40%;
3-vs. CAD 53%
54 na 16%
Kloster et al.74 1979 Chronic stable
CAD
ACS within 6 months,
CHF
51/49 CABG na na na 1-vs. CAD 18%;
2-vs. CAD 36%;
3-vs. CAD 46%
52 11% na
ECSS75 1979 Chronic stable
CAD
na 395/373 CABG na 93% 13% 2-vs. CAD 40%;
3-vs. CAD 53%;
LM-CAD 7%
49 0% 6%
Norris et al.76 1981 CAD s/P.1 MI na 50/50 CABG na na 18% 2-vs. CAD;
3-vs. CAD
51 na na
CASS77 1984 Chronic stable
CAD or s/p MI
LM-CAD, EF, 35% 390/390 CABG na 92% 24% 1-vs. CAD 27%;
2-vs. CAD 40%;
3-vs. CAD 74%
52 10% 9%
VA Cooperative
Study78
1984 Stable angina with
ischaemia
ACS, CHF 332/354 CABG na 94% 38% 1-vs. CAD; 2-vs. CAD;
3-vs. CAD
51 0% 15%
ACME-179,80 1992 1-vs. CAD with
ischaemia or
recent MI
ACS, previous PCI,
MVD, EF, 30%
112/115 PCI PTCA 96% 41% 1-vs. CAD 63 na 18%
TOPS81 1992 Recent MI na 42/45 PCI PTCA 100% na 1-vs. CAD 57 16% 21%
Sievers et al.82 1993 Recent MI,
asymptomatic
1-vs. CAD
Previous MI, diabetes
mellitus
44/44 PCI PTCA 100% 20% 1-vs. CAD 56 na 0%
ACME-283 1997 1-vs. CAD with
ischaemia or
recent MI
ACS, previous PCI,
MVD, EF, 30%
51/50 PCI PCTA 100% 40% 2-vs. CAD na na na
DANAMI67,84 1997/2007 CAD with
ischaemia or
inducible
post-infarct
ischaemia
Refractory angina,
previous
revascularization
503/505 CABG (147)/PCI
(266)
PTCA 82% 20% 1-vs. CAD; 2-vs. CAD;
3-vs. CAD
56 18% 35%
ACIP85 1997 Silent ischaemia Recent ACS, CCS IV,
NYHA III/IV, PCI
within 6 mo, CABG
within 3 mo, LMD
192/366 CABG/PCI PTCA 89% 29% 1-vs. CAD; 2-vs. CAD;
3-vs. CAD
61 14% 16%
RITA-286,87 1997/2003 Chronic stable
angina
Previous
revascularization,
recent ACS,
LM-CAD
504/514 PCI BMS 9% 93% 35% 1-vs. CAD 60%;
2-vs. CAD 33%;
3-vs. CAD 7%
58 18% 9%
Dakik et al.88 1998 CAD with
ischaemia s/p
MI
EF. 35%, 3-vs. CAD 19/22 PCI BMS 29% 100% 9% 1-vs. CAD 44%;
2-vs. CAD 41%;
3-vs. CAD 15%
53 41% na
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Table 3 Continued
Year Inclusion
criteria
Exclusion criteria Number of
patients:
Revasc/OMT
Revasc (PCI,
CABG)
PCI Method
(PTCA, BMS,
DES)
Protocol
Revasc. in
Revasc.Group
Non-protocol
revasc.
in Medical
Group
CAD severity Age
(years)
Female
gender (%)
Diabetes
(%)
Horie et al.89 1998 Subacute anterior
MI
Age . 80 years, hx of
stroke, valvular
disease, renal
failure, LM-CAD
44/39 PCI PTCA na na 1-vs. CAD 61%;
2-vs. CAD 22%;
3-vs. CAD 17%
62 24% 15%
AVERT90 1999 Chronic stable
CAD
Age .80 years, recent
ACS, 3-vs. CAD,
LM-CAD,
EF, 40%
177/164 PCI BMS 30% 94% 12% 1-vs. CAD 56%;
2-vs. CAD 44%
58 16% 27%
MASS I (PCI)91 1999 CAD with
ischaemia
Prior revasc, MI, LV
dysfunction,
LM-CAD
72/72 PCI PTCA 100% 17% 1-vs. CAD 56 42% 18%
MASS I (CABG)91 1999 CAD with
ischaemia
Prior revasc, MI, LV
dysfunction,
LM-CAD
70/72 CABG na 100% 17% 1-vs. CAD 58 42% 19%
TIME92,105 2001/2004 CAD with
ischaemia, age
.75 years
Recent MI 153/148 CABG/PCI na 71% 42% 1-vs. CAD;
2-vs. CAD; TVD
80 42% 34%
Bech et al.124 2001 CAD s/p MI Total occlusion, ACS 90/91 PCI BMS 46% 100% 7% 1-vs. CAD 67%;
2-vs. CAD 28%;
3-vs. CAD 5%
61 34% 12%
TOAT94 2002 CAD s/p anterior
MI
na 32/34 PCI BMS 100% 100% na 1-vs. CAD 59 20% 14%
ALKK95 2003 CAD s/p MI CCS III/IV, .70%
stenosis in
Non-IRA,
indication for
CABG
149/151 PCI BMS 11% 93% 24% 1-vs. CAD 58 14% 16%
MASS II (PCI)96,97 2004/2007 CAD with
ischaemia
Previous revasc, ACS,
EF, 40%, 1-vs.
CAD, LM-CAD
205/203 PCI BMS 72% 95% 24% 2-vs. CAD 42%;
3-vs. CAD 58%
60 30% 32%
MASS II (CABG)96,97 2004/2007 CAD with
ischaemia
Previous revasc, ACS,
EF, 40%, 1-vs.
CAD, LM-CAD
203/203 CABG na 95% 24% 2-vs. CAD 42%;
3-vs. CAD 58%
60 32% 33%
Hambrecht et al.98 2004 CAD with
ischaemia
ACS, recent MI,
EF, 40%, revasc,
age .70 years
50/51 PCI na 100% 6% 1-vs. CAD 30%;
2-vs. CAD 14%;
3-vs. CAD 15%
61 0% 12%
DECOPI99 2004 CAD s/p MI
without MI
Persistent ischaemia,
LM-CAD
109/103 PCI BMS 80% 5% 1.0% 1-vs. CAD 61%;
2-vs. CAD 26%;
3-vs. CAD 7%
57 10% 16%
OAT100 2006 CAD s/p recent
MI
Severe CHF, 3-vs.
CAD, LM-CAD
1082/1084 PCI BMS 79%; DES
8%
100% 9% 1-vs. CAD; 2-vs. CAD 59 22% 21%
INSPIRE101 2006 CAD with
ischaemia and
s/p MI
Cardiogenic shock,
recurrent chest
pain, ACS
104/101 CABG (27)/PCI
(43)
BMS 94% 67% 26% 1-vs. CAD; 2-vs. CAD;
3-vs. CAD 33%;
LM-CAD 12%
63 24% 28%
COURAGE102 2007 CAD CCS IV, refractory
CHF, EF, 30%,
LM-CAD
1149/1138 PCI BMS 91%; DES
3%
96% 33% 1-vs. CAD 31%;
2-vs. CAD 39%;
3-vs. CAD 30%
61 15% 33%
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SWISSI II66 2007 CAD s/p MI na 96/105 PCI na 100% 44% 1-vs. CAD; 2-vs. CAD 55 13% 11%
Nishigaki103 2008 CAD with
ischaemia
3-vs. CAD, chronic
occlusion, ACS,
LVEF, 50%, renal
failure
192/188 PCI PTCA 15%; BMS
76%
na na 1-vs. CAD 68%;
2-vs. CAD 32%
64 25% 40%
BARI 2D104 2009 Chronic stable
CAD with DM
Urgent revasc,
LM-CAD, severe
CHF,
Creat . 2 mg/dL,
hepatic failure
1176/1192 CABG (378)/PCI
(798)
na; PTCA 9%;
BMS 56%;
DES 35%
95% 42% (13% within 6
months)
1-vs. CAD; 2-vs. CAD;
3-vs. CAD 31%
62 30% 100%
Clinical outcome
Study Year Follow-up
(years)
Primary endpoint Overall death Cardiac death MI
Number of
patients:
Revasc/OMT
Revasc (%) Medical Rx (%) Revasc (%) Medical Rx (%) Revasc (%) Medical
Rx (%)
Mathur and Guinn73 1977 3 na 56/60 5.5 11.7 na na 10.9 16.7
Kloster et al.74 1979 3 MACE 51/49 7.8 10.2 na na 19.6 16.3
ECSS75 1979 2 Death and MI 395/373 5.3 7.8 na na na na
Norris et al.76 1981 4.5 na 50/50 12 10 10 10 na na
CASS77 1984 5 Deasth and MI 390/390 6.7 8.7 na na 13.6 11.0
VA Cooperative
Study78
1984 11.2 Death 332/354 42 43 na na na na
ACME-179,80 1997 2.4 Death, MI, rehosp. and
revasc.
112/115 13.9 13.4 na na 12.2 7.1
TOPS81 1992 1 LVEF with exercise 42/45 0 0 0 0 9.5 2.2
Sievers et al.82 1993 2 na 44/44 0 2.3 0 2.3 4.5 0
ACME-283 1997 3 Death, MI, rehosp. and
revasc.
51/50 17.6 20 na na 11.8 12
DANAMI67,84 1997/2007 2.4 Death, MI and rehosp.
for ACS
503/505 3.6 4.4 na na 5.6 10.5
ACIP85 1997 2 Death, MI, rehosp. and
revasc.
192/366 2.2 5.5 na na 3.6 4.9
RITA-286,87 1997/2003 7 Death and MI 504/514 8.5 8.4 4.0 4.7 6.3 4.5
Dakik et al.88 1998 1 LV perfusion defect  19/22 4.8 4.3 4.8 4.3 9.5 0
Horie et al.89 1998 5 Cardiac death, MI and
CHF
44/39 2.3 12.8 na na 6.8 17.9
AVERT90 1999 1.5 Cardiac death, cardiac
arrest, MI, CVA,
rehosp. and revasc.
177/164 0.6 0.6 0.6 0.6 2.8 2.4
MASS I (PCI)91 1999 5 Cardiac death, MI and
rehosp.
72/72 8.3 8.3 5.6 2.8 5.6 4.2
MASS I (CABG)91 1999 5 Cardiac death, MI and
rehosp.
70/72 2.9 8.3 2.9 2.8 4.3 4.2
TIME92,105 2001/2004 4.1 Death, MI and ACS 153/148 29.4 27.0 20.9 22.3 11.8 12.2
Bech et al.124 2001 2 Death, MI and revasc. 90/91 2.2 4.4 1.1 2.2 3.3 0
TOAT94 2002 1 LV end-systolic volume 32/34 6.3 2.9 na na 9.4 2.9
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Table 3 Continued
Year Inclusion
criteria
Exclusion criteria Number of
patients:
Revasc/OMT
Revasc (PCI,
CABG)
PCI Method
(PTCA, BMS,
DES)
Protocol
Revasc. in
Revasc.Group
Non-protocol
revasc.
in Medical
Group
CAD severity Age
(years)
Female
gender (%)
Diabetes
(%)
ALKK95 2003 4.7 Death, MI, rehosp. and
revasc.
149/151 4.0 11.3 2.7 9.3 6.7 7.9
MASS II (PCI)96,97 2004 5 Death, Q-wave MI and
revasc.
205/203 15.5 16.2 11.6 12.3 11.2 15.3
MASS II (CABG)96,97 2004 1 Death, Q-wave MI and
revasc.
203/203 12.8 16.2 7.9 12.3 8.3 15.3
Hambrecht et al.98 2004 1 Cardiac death, MI,
CVA, rehosp. and
revasc.
50/51 0 0 0 0 2.0 0
DECOPI99 2004 3 Cardiac death, MI, and
ventricular
tachyarrhythmia
109/103 7.3 8.7 5.5 6.8 3.7 2.9
OAT100 2006 4 Death, MI, and CHF 1082/1084 9.1 9.4 6.3 5.0 7.0 5.3
INSPIRE101 2006 1 LV perfusion defect  104/101 1.9 1.0 1.9 1.0 4.8 6.9
COURAGE102 2007 4.6 Death and MI 1149/1138 7.4 8.3 2.0 2.2 12.4 11.2
SWISSI II66 2007 10.2 Cardiac death, MI and
revasc.
96/105 6.3 21.0 3.1 21.0 11.5 38.1
Nishigaki103 2008 3.25 Death, CVA and
rehosp.
192/188 2.9 3.9 na na na na
BARI 2D104 2009 5.3 Death, MI and CVA 1176/1192 11.7 12.2 na na na na
CAD, coronary artery disease; MI, myocardial infarction; na, not available; CVA, cerebrovascular accident.
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CABG (20.9%) than those treated medically (29.9%, P ¼ 0.01),
whereas no difference was observed in the PCI stratum (23.4 vs.
20.8%, P ¼ 0.15).
In contrast, the TIME study, which randomly assigned 301
elderly patients (.75 years of age) to an invasive or medical strat-
egy without baseline coronary angiography, reported no difference
in mortality according to initial treatment allocation. Of note,
during longer-term follow-up to 4 years survival was significantly
lower in patients undergoing revascularization (80%) compared
with those not being revascularized (61%, P ¼ 0.003) irrespective
of the initial treatment assignment.105
Since none of these studies was powered to detect a difference
in mortality or subsequent MI, meta-analyses are required to assess
the impact of revascularization on patient outcome. A
meta-analysis of the first seven trials comparing CABG with
medical therapy established a reduction in mortality in selected
patients following CABG with the benefit being proportional to
the number of diseased coronary arteries and the degree of myo-
cardial ischaemia.106 In contrast, early systematic reviews compar-
ing PCI (mainly balloon angioplasty) with medical treatment in
relatively small numbers of patients failed to show a difference in
the risk of death or MI.107–109 More recently, however, a
meta-analysis of 17 randomized trials compared medical treatment
with PCI in 7513 patients with an average follow-up of 51
months.110 Revascularization was performed in 92% of patients
allocated to PCI (43% balloon angioplasty, 41% stents, 8%
CABG), whereas 28% of patients allocated to medical treatment
underwent revascularization early or during follow-up. At
follow-up, the risk of overall mortality was significantly reduced
by 20% in favour of PCI (OR ¼ 0.80, 95% CI 0.64–0.99) with no
apparent heterogeneity across trials (I2 ¼ 17%), whereas the risk
of MI was similar among both groups (OR ¼ 0.90, 95% CI 0.66–
1.23). Exclusion of four studies allowing both CABG and PCI as
treatment option did not impact the results regarding all-cause
mortality. The benefit of revascularization became more pro-
nounced with follow-up periods beyond 5 years. A network
meta-analysis, however, did not find a significant reduction in mor-
tality or MI for balloon angioplasty (PTCA) compared with medical
therapy, nor with bare-metal stents compared with PTCA or
drug-eluting stents compared with bare-metal stents. The different
results of these meta-analyses reflect differences in the analytic
methodology and trial selection, but also illustrate that any mor-
tality benefits of PCI are modest at best.111
The most recent review compared medical treatment with surgi-
cal or percutaneous revascularization in 13 121 patients enrolled
into 17 PCI, 6 CABG, and 5 trials using either revascularization strat-
egy.112 Consistent with the previous meta-analysis, which covered
most of the same trials, mortality was lower after revascularization
than in the medical therapy group (7.9 vs. 9.8%, OR ¼ 0.74, 95% CI
0.63–0.88). These findings remained consistent following exclusion
of studies in patients with recent MI (OR ¼ 0.77, 95%CI 0.65–0.91).
The treatment effect appeared more pronounced in early studies
comparing CABG with medical treatment (OR ¼ 0.62, 95% CI
0.50–0.77) than in the more recent studies comparing PCI with
medical treatment (OR ¼ 0.82, 95% CI 0.68–0.99). Furthermore,
confidence intervals overlapped widely and an analysis of variance
revealed no significant difference between the two revascularization
strategies (P ¼ 0.33)(Figure 5). Again, there was no difference in the
risk of MI between both groups.
Recently, FFR was comparedwith angiography for guiding PCI in a
large-scale randomized trial with 1005 patients (FAME).113 At 1 year,
routine measurement of FFR to select lesions requiring PCI (FFR ,
80%) was associated with lower rates of death or MI (7.3 vs. 11.1%,
P ¼ 0.04) than PCI guided by angiography alone. Similarly, deferring
revascularization in patients with non-significant lesions as deter-
mined by FFR appeared safe as shown during the 5 year follow-up
Figure 4 Cumulative rate of revascularization in the BARI-2D trial. (‘cross-over’) The substantial proportion of patients allocated to medical
treatment subsequently undergoing revascularization considerably contributes to the lack of differences in treatment effect between the two
strategies. Obtained with permission from Frye et al.104
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of the randomized DEFER study with similar rates of death or MI
(,1%/year) among patients treated medically and those undergoing
PCI.40 These findings imply that part of the patients enrolled in pre-
vious trials were unlikely to benefit from PCI or CABG if they had
no, or limited myocardial ischaemia and suggest that functional
assessment of lesions (ischaemia or none) may help to identify
those who benefit from revascularization.
Revascularization and quality of life
Compared with medical therapy, revascularization by PCI or CABG
has been consistently shown to more effectively relieve angina,
reduce the use of anti-angina drugs, improve exercise capacity and
quality of life (Tables 4 and 5).107,114 In the RITA-2 and
COURAGE studies angina frequency and quality of life were
assessed systematically.115 PCI relieved angina and improved self-
assessed health status to a greater degree than medical therapy
alone up to 24 months. This benefit from PCI was greatest among
patients with severe and frequent angina, and one-third of patients
in the medical therapy group subsequently underwent PCI for
symptom relief during follow-up. Freedom from angina was 66% in
the PCI group of COURAGE when compared with 81% in the
PCI group of FAME, a difference which may be explained by the
near exclusive use of drug-eluting stents, reducing the rate of reste-
nosis, in the latter.113 Indeed, a recent meta-analysis showed
sequential reductions in repeat revascularization with bare-metal
stents compared with balloon angioplasty (risk reduction 32%)
and with drug-eluting stents compared with bare-metal stents
(risk reduction 56%), which undoubtedly impact quality of life.111
The debate
The presentation and publication of the COURAGE study caused a
heated debate, particularly among colleagues from the USA.17,116
The validity of COURAGE was called into question owing to the
inclusion of only 6.4% of the screened population, the relatively
high proportion of patients lost to follow-up, the inclusion of
patients with little or no ischaemia, allocation of treatment only
after coronary angiography excluding patients at increased risk,
and question marks regarding the quality of revascularization pro-
cedures in various health care settings. Moreover, the study was
judged to be underpowered due to lower than expected event
rates despite protocol amendments allowing for more liberal
Figure 5 Impact of revascularization on mortality in patients with chronic stable coronary artery disease. Mortality is significantly reduced for
the comparison of both coronary artery bypass surgery (OR ¼ 0.62, 95% CI 0.50–0.77) and percutaneous coronary intervention (OR ¼ 0.82,
95% CI 0.68–0.99) compared with medical treatment alone. Obtained with permission from Jeremias et al.112
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Freedom from angina in trials comparing a
routine invasive with an initial non-invasive strategy in
patients with stable coronary artery disease
Study Routine
revascularization, %
Initial medical
treatment, %
Mathur and Guinn73 62 7
Kloster et al.74 69 47
ACME-179,80 63 48
Sievers et al.82 80 75
ACME-283 53 36
RITA-286,87 63 46
MASS I (CABG)91 73 26
MASS I (PCI)91 65 26
Bech et al.124 51 70
ALKK95 77 61
MASS II (CABG)96,97 74 55
MASS II (PCI)96,97 77 55
DECOPI99 93 89
OAT100 89 91
COURAGE102 74 72
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inclusion and extension of follow-up. The definition of peri-
procedural infarction with any increase of CK-MB was felt oversen-
sitive without clear prognostic relevance and not adhering to rec-
ommendations of published guidelines thus disadvantaging the PCI
group.41 Finally, cross-over from medical treatment to subsequent
revascularization was not considered an adverse event but said to
camouflage potential differences in outcome between the
two treatment regimens. Notwithstanding these limitations,
COURAGE and other individual studies have failed to show any
superiority of PCI in terms of ischaemic endpoints (Table 3).
Earlier trials comparing an initially invasive- or non-invasive strategy
in stable CAD were relatively small and under powered, particularly
when compared with studies which assess preventive treatment
with drugs including several thousand of patients.24,55,56,117,118 Yet
the results of meta-analyses of revascularization trials have shown
a consistent benefit in terms of survival for CABG and a modest
survival benefit for PCI.106,110,112 Moreover, the data from large
observational studies support the notion of a graded survival
benefit derived from both revascularization procedures.71,72
The debate elicited by COURAGE has called our attention to
the fact that, apart from many patients who appropriately benefit
from PCI and CABG, the indications for such procedures in
other patients are less well defined. Revascularization is primarily
directed against the elimination of myocardial ischaemia as well
as symptoms of affected patients. Thus, treatment of coronary
lesions without ischaemia or of patients without symptoms is
not beneficial. Yet, about half of the patients undergoing elective
PCI for stable angina in the UK119 and in the USA14 do not
undergo a stress test to document ischaemia before the pro-
cedure. Worldwide, inappropriate revascularization procedures
increase healthcare cost and use scarce hospital resources.
Conclusions
All patients with atherosclerosis, including patients with angina pec-
toris, benefit from life long drug therapy in addition to a healthy
lifestyle. In addition coronary revascularization is appropriate at
some time or several times during their lifespan, either for episodes
of ACSs or for treatment of myocardial ischaemia. Optimal manage-
ment of CAD, as presented in ESC guidelines18,52 and similar publi-
cations includes: (i) appropriate lifestyle, i.e. no smoking, a healthy
diet, weight control, and regular exercise; (ii) detection and treatment
of diseases and conditions which increase the risk of atherosclerosis,
in particular hypertension, diabetes, and hypercholesterolaemia; (iii)
drug therapy to lower LDL cholesterol (statins) in subjects at high
risk for new or recurrent atherosclerosis events; (iv) additional
preventive therapy with aspirin, other anti-thrombotic agents,
ACE-inhibitors, and b blockers in patients with known atherosclero-
sis; (v) symptomatic treatment with nitrates, b blockers, calcium
channel blockers, and other anti-angina drugs; and (vi) revasculariza-
tion by PCI or CABG in selected patients.
Revascularization exerts favourable effects on symptoms, qualityof
life, exercise capacity, and survival, particularly in thosewith extensive
CAD and documented moderate-to-severe ischaemia. Accordingly,
CABG and PCI should be considered a valuable adjunct rather than
an alternative to medical therapy. Of note, the benefits of revascular-
ization are associated with a low peri-procedural risk and therefore
justify their implementation for symptomatic as well as prognostic
reasons. As with most other therapeutic interventions in medicine,
the relief of symptoms remains a noble task of physicians caring for
patients with stable CAD, particularly in today’s executive society
where only few would opt to accept angina symptoms impeding
their otherwise active life style.
The debate should not be medical vs. revascularization therapy
but rather which patients should be offered revascularization and
when. The timing of revascularization requires careful consider-
ation. Patients with no or mild symptoms and little ischaemia can
safely be treated with medical treatment alone. Conversely,
patients with moderate-to-severe symptoms and/or extensive
ischaemia should be strongly considered for revascularization
therapy. Non-invasive (MS-CT, perfusion scintigraphy, or
PET-CT) or invasive (FFR) identification of lesions giving rise to
ischaemia may further improve outcome in patients submitted to
revascularization. Patients undergoing coronary angiography for
symptomatic CAD with an anatomy amenable to PCI should be
offered the possibility to undergo revascularization during the
same session (ad hoc) as treatment options (medical treatment,
CABG, and PCI) are known and can be discussed in advance,
sparing yet another invasive procedure. Finally, patient preference
must be carefully weighed in the overall treatment selection.
We call upon our colleagues to review their practice and to
comply with the recommendations for optimal medical
management of all patients with angina and stable CAD as well
as optimal use of PCI and CABG in appropriately selected patients.
Conflict of interest: none declared.
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